Related Experiment Videos

The effect of TNFalpha blockade in complicated, refractory Kawasaki disease

E V Stenbøg1, B Windelborg, A Hørlyck

  • 1Department of Paediatrics, Aarhus University Hospital, Section SKS, DK-8200 Aarhis N, Denmark. elisabethsteinboeg@oncable.dk

Scandinavian Journal of Rheumatology
|August 3, 2006
PubMed

Insights

Infliximab offers a promising treatment for severe Kawasaki disease (KD) unresponsive to standard therapies. This biological agent effectively reduced inflammation and coronary aneurysms in infants with refractory KD.

Area of Science:

  • Pediatric Rheumatology
  • Immunology

Background:

  • Kawasaki disease (KD) is a childhood systemic vasculitis with elevated proinflammatory cytokines.
  • Intravenous immunoglobulin (IVIG) is standard treatment, but refractory cases lack guidelines.
  • Biological agents targeting cytokines are a potential future therapy.

Observation:

  • Two infants with severe KD and coronary/extracoronary aneurysms showed resistance to IVIG, aspirin, and corticosteroids.
  • These patients were treated with infliximab, a biologic agent targeting tumor necrosis factor alpha (TNFalpha).

Findings:

  • Infliximab treatment led to prompt and sustained clinical improvement within days.
  • Significant regression of coronary and extracoronary aneurysms was observed within weeks of infliximab administration.
  • This suggests infliximab's efficacy in managing severe, refractory KD.

Implications:

  • Infliximab may represent a viable therapeutic option for severe KD cases refractory to current treatments.
  • Early intervention with biologics like infliximab could prevent long-term cardiovascular complications in KD patients.
  • Further research is warranted to establish optimal protocols for biologic therapy in Kawasaki disease.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...